Regencell Bioscience (RGC) has had the highest return since November 1, 2021 by a mid-cap US stock, returning 4,563%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 4,562.97% |
QMMM Holdings Limited Ordinary Shares (QMMM) | 3,880% |
Verona Pharma PLC ADR (VRNA) | 1,992.17% |
Sezzle (SEZL) | 1,949.01% |
Modine Manufacturing (MOD) | 1,211.92% |
Powell Industries (POWL) | 1,151.47% |
ADMA Biologics (ADMA) | 1,001.52% |
Rhythm Pharmaceuticals (RYTM) | 772.9% |
Abivax SA American Depositary Shares (ABVX) | 708.36% |
Innodata (INOD) | 676.14% |
IES (IESC) | 620.53% |
Applied Digital (APLD) | 618.67% |
Solaris Energy Infrastructure (SEI) | 594.62% |
Argan (AGX) | 569.41% |
Centrus Energy (LEU) | 539.32% |
Belite Bio Inc ADR (BLTE) | 534.24% |
Vista Oil Gas ADR (VIST) | 479.72% |
Viking Therapeutics (VKTX) | 473.68% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 467.49% |
Soleno Therapeutics (SLNO) | 466.71% |
Madrigal Pharmaceuticals (MDGL) | 450.2% |
InterDigital (IDCC) | 442.93% |
Perpetua Resources (PPTA) | 437.29% |
Primoris Services (PRIM) | 402.33% |
United States Lime & Minerals (USLM) | 393.16% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
